Kos Biotechnology Partners Invests in Fathom Therapeutics' Series A Financing
Kos Biotechnology Partners, through its inaugural fund Kos BioVentures, has participated in a $55 million Series A financing round for Fathom Therapeutics. The oversubscribed funding round was led by Sutter Hill Ventures and aims to advance Fathom’s proprietary Microcosmos platform, which integrates quantum chemistry, physics-based molecular simulations, and artificial intelligence to discover next-generation small molecule medicines. Fathom Therapeutics focuses on modeling protein-drug interactions at atomic resolution to target biological pathways previously considered undruggable. The company's leadership team includes prominent computational scientists responsible for significant advancements in molecular simulation and supercomputing. This investment underscores a growing market trend toward the intersection of AI, physics, and experimental biology in biopharmaceutical innovation.
Topics: Artificial Intelligence Biotechnology Investment Drug Discovery Series A Financing